Table 1.
Demographic and clinical characteristics of human immunodeficiency virus-1 infected patients who received a tuberculosis enzyme-linked immunospot and tuberculin skin tests (TST).
| Characteristics | Total group (n = 201) | TST group (n = 72) |
|---|---|---|
| Age, median (IQR) | 40 (33–46) | 40 (33–46) |
| Male, no. (%) | 119 (59) | 41 (57) |
| Ethnic origin | ||
| African, no. (%) | 102 (51) | 39 (54) |
| White, no. (%) | 69 (34) | 25 (35) |
| Asian/other, no. (%) | 30 (15) | 8 (11) |
| CD4 T cell count | ||
| Median (IQR) | 213 (77–367) | 261 (120–455) |
| < 300 cells/µl, no. (%) | 129 (64) | 39 (54) |
| < 200 cells/µl, no. (%) | 96 (48) | 25 (35) |
| < 100 cells/µl, no. (%) | 61 (30) | 16 (22) |
| BCG,† no. (%) | n.d. | 49 (68) |
| ART, no. (%) | 118 (59) | 43 (60) |
| Viral load | ||
| < 50 copies/ml, no. (%) | 87 (43) | 35 (49) |
†
Bacille Calmette–Guérin (BCG) vaccination status determined on the basis of clinical history and the presence of a scar. IQR: interquartile range; n.d. not determined; ART: anti-retroviral therapy.